Your browser doesn't support javascript.
loading
Matched Comparison of Hearing Outcomes in Patients With Vestibular Schwannoma Treated With Stereotactic Radiosurgery or Observation.
Schnurman, Zane; Gurewitz, Jason; Smouha, Eric; McMenomey, Sean O; Roland, J Thomas; Golfinos, John G; Kondziolka, Douglas.
Afiliação
  • Schnurman Z; Department of Neurosurgery, NYU Langone Health, New York, New York, USA.
  • Gurewitz J; Department of Neurosurgery, NYU Langone Health, New York, New York, USA.
  • Smouha E; ENT and Allergy Associates, Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • McMenomey SO; Department of Otolaryngology-Head and Neck Surgery, NYU Langone Health, New York, New York, USA.
  • Roland JT; Department of Otolaryngology-Head and Neck Surgery, NYU Langone Health, New York, New York, USA.
  • Golfinos JG; Department of Neurosurgery, NYU Langone Health, New York, New York, USA.
  • Kondziolka D; Department of Neurosurgery, NYU Langone Health, New York, New York, USA.
Neurosurgery ; 91(4): 641-647, 2022 10 01.
Article em En | MEDLINE | ID: mdl-36001782
ABSTRACT

BACKGROUND:

Previous studies comparing hearing outcomes in patients managed with stereotactic radiosurgery (SRS) and a watch-and-wait strategy were limited by small sample sizes that prevented controlling for potential confounders, including initial hearing status, tumor size, and age.

OBJECTIVE:

To compare hearing outcomes for patients with vestibular schwannomas (VS) managed with observation and SRS while controlling for confounders with propensity score matching.

METHODS:

Propensity score matching was used to compare 198 patients with unilateral VS with initial serviceable hearing (99 treated with SRS and 99 managed with observation alone) and 116 with initial class A hearing (58 managed with SRS and 58 with observation), matched by initial hearing status, tumor volume, age, and sex. Kaplan-Meier survival methods were used to compare risk of losing class A and serviceable hearing.

RESULTS:

Between patients with VS managed with SRS or observation alone, there was no significant difference in loss of class A hearing (median time 27.2 months, 95% CI 16.8-43.4, and 29.2 months, 95% CI 20.4-62.5, P = .88) or serviceable hearing (median time 37.7 months, 95% CI 25.7-58.4, and 48.8 months, 95% CI 38.4-86.3, P = .18). For SRS patients, increasing mean cochlear dose was not related to loss of class A hearing (hazard ratio 1.3, P = .17) but was associated with increasing risk of serviceable hearing loss (hazard ratio of 1.5 per increase in Gy, P = .017).

CONCLUSION:

When controlling for potential confounders, there was no significant difference in loss of class A or serviceable hearing between patients managed with SRS or with observation alone.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuroma Acústico / Radiocirurgia / Perda Auditiva Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neuroma Acústico / Radiocirurgia / Perda Auditiva Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article